Pseudomonal infection in cystic fibrosis: the battle continues (Q34358536)

1 August 2017

1 reference

title

Pseudomonal infection in cystic fibrosis: the battle continues (English)

1 reference

1 August 2017

0 references

Sarah Elkin

1

1 reference

1 August 2017

Duncan Geddes

series ordinal

2

1 reference

1 August 2017

publication date

1 December 2003

1 reference

Expert Review of Anti-infective Therapy

1 August 2017

published in

1 reference

1 August 2017

volume

1

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

609-618

1 reference

Identification of the cystic fibrosis gene: chromosome walking and jumping

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Pathogenesis of the pseudomonas lung lesion in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Relative ion permeability of normal and cystic fibrosis nasal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

An overview of the pathogenesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Biofilms as complex differentiated communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

21 January 2018

Vaccines and vaccination

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Diffuse panbronchiolitis and cystic fibrosis: East meets West

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Rational parameters for antibiotic therapy in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Acyl-homoserine lactone acylase from Ralstonia strain XJ12B represents a novel and potent class of quorum-quenching enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.609

21 January 2018

Identifiers

DOI

10.1586/14787210.1.4.609

1 reference

1 August 2017

1 reference